A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy

BACKGROUND: Pertussis vaccination during pregnancy can prevent 91% of infant infections. In 2015, antenatal pertussis vaccination programs were introduced across Australia. METHODS: To monitor the safety of this program, pregnant women who received trivalent influenza vaccine (TIV) and/or diphtheri...

Full description

Bibliographic Details
Main Authors: Regan, Annette, Tracey, L., Blyth, C., Richmond, P., Effler, P.
Format: Journal Article
Published: Elsevier 2016
Online Access:http://hdl.handle.net/20.500.11937/47222
_version_ 1848757775045230592
author Regan, Annette
Tracey, L.
Blyth, C.
Richmond, P.
Effler, P.
author_facet Regan, Annette
Tracey, L.
Blyth, C.
Richmond, P.
Effler, P.
author_sort Regan, Annette
building Curtin Institutional Repository
collection Online Access
description BACKGROUND: Pertussis vaccination during pregnancy can prevent 91% of infant infections. In 2015, antenatal pertussis vaccination programs were introduced across Australia. METHODS: To monitor the safety of this program, pregnant women who received trivalent influenza vaccine (TIV) and/or diphtheria-tetanus-acellular pertussis vaccine (dTpa) were surveyed by text message seven days post-vaccination about possible adverse events following immunization (AEFI). Univariate logistic regression models were used to calculate the odds of reporting an AEFI following dTpa compared to TIV. Similar analyses were used to compare AEFI reported by women who received a previous dose of dTpa in 2011/2012 as part of a state-wide cocooning program. RESULTS: Of 5155 women, 4347 (84.3%) replied; 10.8% indicated they experienced an AEFI. There was no difference in the proportion of women who reported any reaction by vaccine; however, women who received dTpa were more likely to report a local reaction than women who received TIV (7.1% and 3.2%, respectively; OR: 2.29; 95% CI: 1.61-3.26). There was evidence suggesting local reactions were more common among women with a previous dose of dTpa (11.4%) compared to women with no previous dose (6.0%; OR: 2.00; 95% CI: 0.95-4.25); 11 (0.3%) women reported attending a hospital emergency department. Subsequent follow-up indicated symptoms resolved and mother and infant were healthy. There was no difference in the proportion of women attending hospital by vaccine (p > 0.05). DISCUSSION: Data on systemic and local reactions following receipt of TIV and dTpa during pregnancy support the safety of antenatal vaccination.
first_indexed 2025-11-14T09:33:27Z
format Journal Article
id curtin-20.500.11937-47222
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:33:27Z
publishDate 2016
publisher Elsevier
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-472222017-09-13T14:10:54Z A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy Regan, Annette Tracey, L. Blyth, C. Richmond, P. Effler, P. BACKGROUND: Pertussis vaccination during pregnancy can prevent 91% of infant infections. In 2015, antenatal pertussis vaccination programs were introduced across Australia. METHODS: To monitor the safety of this program, pregnant women who received trivalent influenza vaccine (TIV) and/or diphtheria-tetanus-acellular pertussis vaccine (dTpa) were surveyed by text message seven days post-vaccination about possible adverse events following immunization (AEFI). Univariate logistic regression models were used to calculate the odds of reporting an AEFI following dTpa compared to TIV. Similar analyses were used to compare AEFI reported by women who received a previous dose of dTpa in 2011/2012 as part of a state-wide cocooning program. RESULTS: Of 5155 women, 4347 (84.3%) replied; 10.8% indicated they experienced an AEFI. There was no difference in the proportion of women who reported any reaction by vaccine; however, women who received dTpa were more likely to report a local reaction than women who received TIV (7.1% and 3.2%, respectively; OR: 2.29; 95% CI: 1.61-3.26). There was evidence suggesting local reactions were more common among women with a previous dose of dTpa (11.4%) compared to women with no previous dose (6.0%; OR: 2.00; 95% CI: 0.95-4.25); 11 (0.3%) women reported attending a hospital emergency department. Subsequent follow-up indicated symptoms resolved and mother and infant were healthy. There was no difference in the proportion of women attending hospital by vaccine (p > 0.05). DISCUSSION: Data on systemic and local reactions following receipt of TIV and dTpa during pregnancy support the safety of antenatal vaccination. 2016 Journal Article http://hdl.handle.net/20.500.11937/47222 10.1016/j.vaccine.2016.03.084 Elsevier restricted
spellingShingle Regan, Annette
Tracey, L.
Blyth, C.
Richmond, P.
Effler, P.
A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy
title A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy
title_full A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy
title_fullStr A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy
title_full_unstemmed A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy
title_short A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy
title_sort prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy
url http://hdl.handle.net/20.500.11937/47222